WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Tips for Negotiating a Third-Party Subpoena in a Merger Investigation
Alerts
June 21, 2017

Humana recently lost its effort to limit third-party discovery requests served by the Federal Trade Commission (FTC) in its ongoing Walgreens/Rite Aid investigation. Typically, negotiations over the scope of third-party subpoenas in an antitrust investigation (whether at the U.S. Department of Justice (DOJ) or the FTC) are resolved through negotiations with the staff attorneys investigating the transaction. In this instance, Humana invoked rules that enable third parties to petition the FTC to limit or quash the discovery after meeting and conferring with staff.1

In its motions, Humana chronicled the negotiations with the FTC over two separate civil investigative demands (CIDs) and an additional subpoena for testimony.2Humana and the FTC reached agreement on two of the specific CID requests, but after repeated attempts, failed to do so on two others. The FTC denied Humana's petition, ordering Humana to respond.3The FTC reasoned that the information requested was directly relevant to the investigation, largely unavailable from other sources, and that Humana failed to support its claim that complying with the subpoena would cause undue burden. The FTC has since filed an emergency petition with the U.S. District Court for the District of Columbia requesting that the court require Humana to comply with the subpoena.

Humana's motion highlights an issue that many companies face in the context of merger investigations. That is, government merger investigations often involve broad discovery requests on third-party market participants, including competitors of the merging parties, the merging parties' business partners (e.g., suppliers, distributors, consultants, and investment bankers), and other industry players. These requests are costly and hard to avoid outright (as evidenced by Humana's latest effort).

However, there are a few things third parties can do to limit the burden:

  1. Be Prepared. Work with counsel to identify employees and shared files likely to have information covered by the subpoena. Having this information (and knowing what you do not have) at the outset can facilitate productive engagement with the antitrust agency.
  2. Ask Questions About the Requests. Requests often appear to be duplicative, and engaging with the agency on their reasoning for specific requests may lend insight into additional ways the request can be narrowed or focused.
  3. Offer a Counter Proposal. Once engaged in discussions with the agency, be proactive in identifying ways in which the subpoena that could be modified and/or reduced. This can include identifying the specific employees' files where information will be collected, or searched, identifying company shared files with the relevant information, and modifying the date range of the search. Be prepared to explain how the proposal gets the agency the actual set of documents and/or data they are looking for versus extensive information that follows the letter of the subpoena but will result in duplicative or irrelevant information.
  4. Specify the Burden. Be exact in describing the scope of the subpoena's burden by specifying the number of employees' records that would be impacted, whether any of the information requested is held in file storage, the volume of documents that would need to be collected, and the cost of reviewing the files. Be prepared to explain how narrowing the scope of the subpoena to fewer employees or a specific time frame would reduce both the burden and the cost of compliance.

Each subpoena and investigation will have its own facts and circumstances that influence the extent to which a subpoena can be narrowed, but with preparation and early agency discussions, the burden may be reduced. As FTC Acting Chairman Maureen Ohlhausen recently stated: "The FTC must remain able to collect the information we need to enforce the law, but I am certain that we can do this while reducing the burden on businesses, particularly third parties who are not under investigation."4

For more information on third-party subpoenas, merger investigations, or any related matter, please contact Jamillia Ferris, Michelle Yost Hale, or any member of the antitrust practice at Wilson Sonsini.


116 CFR § 2.10.
2https://www.ftc.gov/system/files/documents/petitions-quash/walgreens-boots-alliance/rite-aid-corporation/170607_humana_petition_to_limit_subpoena_duces_tecum.pdf.
3https://www.ftc.gov/system/files/documents/petitions-quash/walgreens-boots-alliance/rite-aid-corporation/170607_humana_ftc_order_denying_petition_.pdf.
4Remarks of Acting Chairman Ohlhausen at the ABA Consumer Protection Conference, February 2, 2017.

Contributors

  • Jamillia P. Ferris
  • Michelle Yost Hale
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.